|
2020-03-18 |
2020-03-17 |
GV
Geplanter Verkauf
|
Ricardo Alonso
See Remarks
Führungsperson
|
2.288
-100.0%
44,25
101.244 USD
|
2.288
-100.0%
|
44,25
|
101.244 USD
|
|
|
2020-03-18 |
2020-03-16 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
Führungsperson
|
10.595
-59.8%
45,16
478.521 USD
|
10.595
-59.8%
|
45,16
|
478.521 USD
|
|
|
2020-02-20 |
2020-02-18 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
Führungsperson
|
10.595
-59.8%
46,61
493.850 USD
|
10.595
-59.8%
|
46,61
|
493.850 USD
|
|
|
2020-01-21 |
2020-01-17 |
GV
Geplanter Verkauf
|
Ricardo Alonso
See Remarks
|
2.285
-50.0%
47,02
107.441 USD
|
2.285
-50.0%
|
47,02
|
107.441 USD
|
|
|
2020-01-16 |
2020-01-15 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10.595
-59.8%
46,95
497.441 USD
|
10.595
-59.8%
|
46,95
|
497.441 USD
|
|
|
2019-12-18 |
2019-12-17 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
Führungsperson
|
10.000
-61.6%
47,08
470.821 USD
|
10.000
-61.6%
|
47,08
|
470.821 USD
|
|
|
2019-12-18 |
2019-12-17 |
GV
Geplanter Verkauf
|
Ricardo Alonso
See Remarks
Führungsperson
|
2.285
-33.3%
47,08
107.568 USD
|
2.285
-33.3%
|
47,08
|
107.568 USD
|
|
|
2019-12-18 |
2019-12-16 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
Führungsperson
|
10.595
-59.8%
47,23
500.351 USD
|
10.595
-59.8%
|
47,23
|
500.351 USD
|
|
|
2019-11-18 |
2019-11-15 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
Führungsperson
|
10.595
-59.8%
46,66
494.319 USD
|
10.595
-59.8%
|
46,66
|
494.319 USD
|
|
|
2019-11-18 |
2019-11-14 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
Führungsperson
|
10.000
-61.6%
46,68
466.808 USD
|
10.000
-61.6%
|
46,68
|
466.808 USD
|
|
|
2019-10-17 |
2019-10-17 |
GV
Geplanter Verkauf
|
Ricardo Alonso
See Remarks
|
2.285
-25.0%
46,70
106.710 USD
|
2.285
-25.0%
|
46,70
|
106.710 USD
|
|
|
2019-10-17 |
2019-10-16 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
|
10.000
-61.6%
46,87
468.726 USD
|
10.000
-61.6%
|
46,87
|
468.726 USD
|
|
|
2019-10-17 |
2019-10-15 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10.595
-59.8%
46,89
496.769 USD
|
10.595
-59.8%
|
46,89
|
496.769 USD
|
|
|
2019-09-16 |
2019-09-16 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
|
10.595
-59.8%
25,26
267.675 USD
|
10.595
-59.8%
|
25,26
|
267.675 USD
|
|
|
2019-09-16 |
2019-09-12 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
|
10.000
-61.6%
25,41
254.050 USD
|
10.000
-61.6%
|
25,41
|
254.050 USD
|
|
|
2019-08-27 |
2019-08-23 |
GV
Geplanter Verkauf
|
Ricardo Alonso
See Remarks
Führungsperson
|
2.285
-20.0%
27,89
63.740 USD
|
2.285
-20.0%
|
27,89
|
63.740 USD
|
|
|
2019-08-27 |
2019-08-23 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
Führungsperson
|
10.000
-61.6%
27,77
277.703 USD
|
10.000
-61.6%
|
27,77
|
277.703 USD
|
|
|
2019-08-27 |
2019-08-23 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
Führungsperson
|
10.595
-59.8%
27,77
294.226 USD
|
10.595
-59.8%
|
27,77
|
294.226 USD
|
|
|
2019-07-18 |
2019-07-17 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
|
10.000
-61.6%
32,95
329.479 USD
|
10.000
-61.6%
|
32,95
|
329.479 USD
|
|
|
2019-07-16 |
2019-07-15 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
|
4.216
-37.2%
33,29
140.338 USD
|
4.216
-37.2%
|
33,29
|
140.338 USD
|
|
|
2019-07-16 |
2019-07-15 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
|
6.379
-36.0%
32,97
210.309 USD
|
6.379
-36.0%
|
32,97
|
210.309 USD
|
|
|
2019-06-25 |
2019-06-21 |
GV
Geplanter Verkauf
|
Ricardo Alonso
See Remarks
|
2.857
-20.0%
23,72
67.782 USD
|
2.857
-20.0%
|
23,72
|
67.782 USD
|
|
|
2019-06-19 |
2019-06-18 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
|
414
-6.2%
23,09
9.560 USD
|
414
-6.2%
|
23,09
|
9.560 USD
|
|
|
2019-06-19 |
2019-06-18 |
GV
Geplanter Verkauf
|
Read Simon
Chief Scientific Officer
|
9.586
-59.0%
22,21
212.908 USD
|
9.586
-59.0%
|
22,21
|
212.908 USD
|
|
|
2019-06-19 |
2019-06-17 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
|
7.184
-50.2%
22,04
158.363 USD
|
7.184
-50.2%
|
22,04
|
158.363 USD
|
|
|
2019-06-19 |
2019-06-17 |
GV
Geplanter Verkauf
|
Farzaneh-Far Ramin
Chief Medical Officer
|
3.411
-19.2%
21,41
73.021 USD
|
3.411
-19.2%
|
21,41
|
73.021 USD
|
|
|
2018-12-14 |
2018-12-14 |
K
Kauf
|
Shah Rajeev M.
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
1.006.452
+26.1%
15,50
15.600.006 USD
|
1.006.452
+26.1%
|
15,50
|
15.600.006 USD
|
|
|
2018-12-14 |
2018-12-14 |
K
Kauf
|
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
|
645.161
+11.8%
15,50
9.999.996 USD
|
645.161
+11.8%
|
15,50
|
9.999.996 USD
|
|
|
2018-12-14 |
2018-12-12 |
K
Kauf
|
RA CAPITAL MANAGEMENT, LLC
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
1.006.452
+26.1%
15,50
15.600.006 USD
|
1.006.452
+26.1%
|
15,50
|
15.600.006 USD
|
|
|
2018-02-21 |
2018-02-16 |
K
Kauf
|
NEW ENTERPRISE ASSOCIATES 13 LP
Large shareholder
|
2.000.000
+57.3%
6,00
12.000.000 USD
|
2.000.000
+57.3%
|
6,00
|
12.000.000 USD
|
|
|
2018-02-16 |
2018-02-14 |
K
Kauf
|
RA CAPITAL MANAGEMENT, LLC
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
2.500.000
+184.9%
6,00
15.000.000 USD
|
2.500.000
+184.9%
|
6,00
|
15.000.000 USD
|
|
|
2018-02-16 |
2018-02-14 |
K
Kauf
|
Shah Rajeev M.
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
2.500.000
+184.9%
6,00
15.000.000 USD
|
2.500.000
+184.9%
|
6,00
|
15.000.000 USD
|
|
|
2017-06-20 |
2017-06-19 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
3.220
-0.1%
22,02
70.899 USD
|
3.220
-0.1%
|
22,02
|
70.899 USD
|
|
|
2017-06-20 |
2017-06-16 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
53.200
-2.3%
21,24
1.130.207 USD
|
53.200
-2.3%
|
21,24
|
1.130.207 USD
|
|
|
2017-06-12 |
2017-06-08 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
700
-0.0%
22,00
15.400 USD
|
700
-0.0%
|
22,00
|
15.400 USD
|
|
|
2017-06-08 |
2017-06-07 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
4.840
-0.2%
22,11
106.999 USD
|
4.840
-0.2%
|
22,11
|
106.999 USD
|
|
|
2017-06-08 |
2017-06-06 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
7.274
-0.3%
22,98
167.161 USD
|
7.274
-0.3%
|
22,98
|
167.161 USD
|
|
|
2017-06-06 |
2017-06-05 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
4.780
-0.2%
23,11
110.488 USD
|
4.780
-0.2%
|
23,11
|
110.488 USD
|
|
|
2017-06-06 |
2017-06-02 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
14.867
-0.6%
23,47
348.949 USD
|
14.867
-0.6%
|
23,47
|
348.949 USD
|
|
|
2017-06-02 |
2017-06-01 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
10.722
-0.5%
23,89
256.176 USD
|
10.722
-0.5%
|
23,89
|
256.176 USD
|
|
|
2017-06-02 |
2017-05-31 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
35.539
-1.5%
23,94
850.896 USD
|
35.539
-1.5%
|
23,94
|
850.896 USD
|
|
|
2017-05-30 |
2017-05-26 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
5.300
-0.2%
25,14
133.267 USD
|
5.300
-0.2%
|
25,14
|
133.267 USD
|
|
|
2017-05-30 |
2017-05-25 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
53
-0.0%
25,00
1.325 USD
|
53
-0.0%
|
25,00
|
1.325 USD
|
|
|
2017-05-25 |
2017-05-24 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
17.451
-0.7%
25,01
436.364 USD
|
17.451
-0.7%
|
25,01
|
436.364 USD
|
|
|
2017-05-22 |
2017-05-18 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
9.019
-0.4%
25,50
229.964 USD
|
9.019
-0.4%
|
25,50
|
229.964 USD
|
|
|
2017-05-18 |
2017-05-17 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
22.534
-0.9%
25,51
574.901 USD
|
22.534
-0.9%
|
25,51
|
574.901 USD
|
|
|
2017-05-18 |
2017-05-16 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
20.081
-0.8%
26,33
528.725 USD
|
20.081
-0.8%
|
26,33
|
528.725 USD
|
|
|
2017-05-02 |
2017-03-01 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
7.778
-0.3%
20,91
162.658 USD
|
7.778
-0.3%
|
20,91
|
162.658 USD
|
|
|
2017-05-02 |
2017-02-28 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
7.847
-0.3%
20,86
163.670 USD
|
7.847
-0.3%
|
20,86
|
163.670 USD
|
|
|
2017-05-02 |
2017-02-27 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
57.844
-2.3%
20,96
1.212.306 USD
|
57.844
-2.3%
|
20,96
|
1.212.306 USD
|
|
|
2017-05-02 |
2017-02-24 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
5.398
-0.2%
20,93
113.000 USD
|
5.398
-0.2%
|
20,93
|
113.000 USD
|
|
|
2017-05-02 |
2017-02-23 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
4.999
-0.2%
21,04
105.160 USD
|
4.999
-0.2%
|
21,04
|
105.160 USD
|
|
|
2017-05-02 |
2017-02-22 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
749
-0.0%
21,86
16.370 USD
|
749
-0.0%
|
21,86
|
16.370 USD
|
|
|
2016-11-02 |
2016-10-31 |
K
Kauf
|
Novo A/S
Large shareholder
|
246.154
+13.8%
13,00
3.200.002 USD
|
246.154
+13.8%
|
13,00
|
3.200.002 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
SANDELL SCOTT D
Large shareholder
|
338.462
+10.7%
13,00
4.400.006 USD
|
338.462
+10.7%
|
13,00
|
4.400.006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
SANDELL SCOTT D
Large shareholder
|
435
-0.5%
13,00
5.655 USD
|
435
-0.5%
|
13,00
|
5.655 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
KOLLURI KRISHNA KITTU
Large shareholder
|
338.462
+10.7%
13,00
4.400.006 USD
|
338.462
+10.7%
|
13,00
|
4.400.006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
KOLLURI KRISHNA KITTU
Large shareholder
|
435
-0.5%
13,00
5.655 USD
|
435
-0.5%
|
13,00
|
5.655 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
MOTT DAVID M
Large shareholder
|
338.462
+10.7%
13,00
4.400.006 USD
|
338.462
+10.7%
|
13,00
|
4.400.006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
MOTT DAVID M
Large shareholder
|
435
-0.5%
13,00
5.655 USD
|
435
-0.5%
|
13,00
|
5.655 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
MORGENTHALER VENTURE PARTNERS IX LP
Large shareholder
|
263.538
+10.6%
13,00
3.425.994 USD
|
263.538
+10.6%
|
13,00
|
3.425.994 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
MORGENTHALER VENTURE PARTNERS IX LP
Large shareholder
|
340
-0.4%
13,00
4.420 USD
|
340
-0.4%
|
13,00
|
4.420 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
Shah Rajeev M.
Nicht geschäftsführender Verwaltungsratsmitglied
|
161.538
+13.6%
13,00
2.099.994 USD
|
161.538
+13.6%
|
13,00
|
2.099.994 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
RA CAPITAL MANAGEMENT, LLC
Nicht geschäftsführender Verwaltungsratsmitglied
|
161.538
+13.6%
13,00
2.099.994 USD
|
161.538
+13.6%
|
13,00
|
2.099.994 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
BARRETT M JAMES
Large shareholder
|
338.462
+10.7%
13,00
4.400.006 USD
|
338.462
+10.7%
|
13,00
|
4.400.006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
BARRETT M JAMES
Large shareholder
|
435
-0.5%
13,00
5.655 USD
|
435
-0.5%
|
13,00
|
5.655 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
Lettmann Jason
Nicht geschäftsführender Verwaltungsratsmitglied
|
15.633
+0.4%
13,00
203.229 USD
|
15.633
+0.4%
|
13,00
|
203.229 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
Lettmann Jason
Nicht geschäftsführender Verwaltungsratsmitglied
|
114.752
+2.9%
13,00
1.491.776 USD
|
114.752
+2.9%
|
13,00
|
1.491.776 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
Lettmann Jason
Nicht geschäftsführender Verwaltungsratsmitglied
|
263.538
+7.2%
13,00
3.425.994 USD
|
263.538
+7.2%
|
13,00
|
3.425.994 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
Lettmann Jason
Nicht geschäftsführender Verwaltungsratsmitglied
|
340
-0.4%
13,00
4.420 USD
|
340
-0.4%
|
13,00
|
4.420 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
BARRIS PETER J
Large shareholder
|
338.462
+10.7%
13,00
4.400.006 USD
|
338.462
+10.7%
|
13,00
|
4.400.006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
BARRIS PETER J
Large shareholder
|
435
-0.5%
13,00
5.655 USD
|
435
-0.5%
|
13,00
|
5.655 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
KERINS PATRICK J
Large shareholder
|
338.462
+10.7%
13,00
4.400.006 USD
|
338.462
+10.7%
|
13,00
|
4.400.006 USD
|
|
|
2016-10-31 |
2016-10-31 |
V
Verkauf
|
KERINS PATRICK J
Large shareholder
|
435
-0.5%
13,00
5.655 USD
|
435
-0.5%
|
13,00
|
5.655 USD
|
|
|
2016-10-31 |
2016-10-31 |
K
Kauf
|
Weller Harry R
Large shareholder
|
338.462
+10.7%
13,00
4.400.006 USD
|
338.462
+10.7%
|
13,00
|
4.400.006 USD
|
|
